<p>Bicalutamide 50 mg daily is indicated&nbsp;for use in combination&nbsp;therapy&nbsp;with a&nbsp;luteinizing hormone-releasing hormone&nbsp;(LHRH)&nbsp;analog&nbsp;for the treatment of Stage D2 metastatic carcinoma of the&nbsp;prostate.<br />
<br />
Bicalutamide 150 mg daily is not approved&nbsp;for use alone or with other treatments</p>